Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PrECOG 0905
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- NCT03836209 ↗
- Completed
- PrECOG, LLC.
- Standard
We haven't built an HCP commentary report on PrECOG 0905 (gilteritinib, midostaurin and 2 more in Acute Myeloid Leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PrECOG 0905 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 7 | |
| X threads | 6 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gilteritinib; Midostaurin; Daunorubicin; Cytarabine
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 181
- Primary outcomes
- FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction
- Sponsor
- PrECOG, LLC. with Astellas Pharma Inc
- Start
- Dec 6, 2019
- Primary completion
- Oct 17, 2023
- Results posted
- Yes
- Registry record
- NCT03836209 · updated Jul 23, 2026